13 news items
Benchmark Reiterates Buy on Humacyte, Maintains $15 Price Target
HUMA
13 May 24
Benchmark analyst Bruce Jackson reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $15 price target.
Humacyte First Quarter 2024 Financial Results and Business Update
HUMA
10 May 24
opportunity, a portfolio of HAVs, is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, AV
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024
HUMA
6 May 24
, is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, AV access for hemodialysis
Ally Financial Reports Upbeat Earnings, Joins Badger Meter, Genuine Parts And Other Big Stocks Moving Higher On Thursday
ALLY
APOG
AQST
18 Apr 24
to Buy and raised the price target from $35 to $45.
Iridium Communications Inc
Humacyte to Host Virtual KOL Event "Hemodialysis Access: A Crossroads of Care," on March 28, 2024
HUMA
26 Mar 24
, is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, AV access for hemodialysis
c7uxp 32kac2kfmkb97m4z54vpyfwn25xe4yrk1vgby9yg
HUMA
26 Mar 24
Piper Sandler analyst Allison Bratzel maintains Humacyte (NASDAQ:HUMA) with a Neutral and maintains $4 price target.
s5rw9z10vdt7y uv4
HUMA
25 Mar 24
Benchmark analyst Bruce Jackson reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $15 price target.
dqytr
HUMA
22 Mar 24
targeting multiple vascular applications, including vascular trauma repair, AV access for hemodialysis, and peripheral arterial disease. Preclinical
ljwflc6zy5w1vgw580kuzh033p8t435ngrq
HUMA
8 Mar 24
Piper Sandler analyst Matt OBrien maintains Humacyte (NASDAQ:HUMA) with a Neutral and raises the price target from $3 to $4.
45coww3ud9e qu2b
ACIC
ADIL
ARVN
1 Mar 24
. Jefferies analyst Yaron Kinar upgraded Root from Hold to Buy and raised the price target from $10 to $40.
MasTec, Inc
2cws6x9rwan5jce py480y9c2os79
HUMA
1 Mar 24
targeting multiple vascular applications, including vascular trauma repair, arteriovenous ("AV") access for hemodialysis, and peripheral artery
bqlmt752nhe2bzxt6 l7r9z9e
HUMA
29 Feb 24
conditions. Humacyte's initial product candidates, a portfolio of HAVs, are currently in late-stage clinical trials targeting multiple vascular
x1rtbtuwyqrkt6fq1leanb9q6ujdza1dxchtfge 5cidx8sgj
HUMA
29 Feb 24
conditions. Humacyte's initial product candidates, a portfolio of HAVs, are currently in late-stage clinical trials targeting multiple vascular
- Prev
- 1
- Next